Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

H.C. Wainwright analyst Raghuram Selvaraju increased the price target on Replimune Group (NASDAQ:REPL), currently trading at $13.79 with a market cap of $1.06 billion, to $22.00, up from the previous ...

"The £1.4M raised by LFFM London will have a transformative impact on our mission," said Stephanie Kauffman, president of the Melanoma Research Alliance. "This generous support allows us to ...